Dataset Viewer
Auto-converted to Parquet Duplicate
message
stringlengths
3
12.9k
message_type
stringclasses
3 values
message_id
int64
0
2
conversation_id
int64
54.3k
898k
cluster
float64
91
91
__index_level_0__
int64
162k
2.69M
Answer this question truthfully
instruction
0
54,267
91
162,391
Management of AKI following COVID-19 includes antiviral therapies, identifying electrolyte disorders, and intravenous fluid resuscitation. Early diagnosis and treatment of AKI in patients with COVID-19 can avoid the progression of AKI into ESRD and reduce mortality. Treatment of AKI following COVID-19 includes: Cor...
output
1
54,267
91
162,392
What is the term used to refer to acute kidney injury associated with COVID-19?
input
2
54,267
91
162,393
Please summerize the given abstract to a title
instruction
0
77,249
91
231,337
Robust antimicrobial photodynamic therapy with curcumin-poly (lactic-co-glycolic acid) nanoparticles against COVID-19: A preliminary in vitro study in Vero cell line as a model
output
1
77,249
91
231,338
BACKGROUND: In this study, the ability of antimicrobial photodynamic therapy (aPDT) as a treatment approach and adjuvant therapy using curcumin-poly (lactic-co-glycolic acid) nanoparticles (Cur@PLGA-NPs) to inactivate Coronavirus disease 2019 (COVID-19) in plasma was investigated. Furthermore, to verify whether the qua...
input
2
77,249
91
231,339
Please summerize the given abstract to a title
instruction
0
77,408
91
231,814
Interferon gamma immunotherapy in five critically ill COVID-19 patients with impaired cellular immunity: a case series
output
1
77,408
91
231,815
Background Prolonged SARS-CoV-2 shedding has been described in immunocompromised COVID-19 patients, resulting in protracted disease and poor outcome. Specific therapy to improve viral clearance and outcome for this group of patients is currently unavailable. Methods Five critically ill COVID-19 patients with severe def...
input
2
77,408
91
231,816
Please summerize the given abstract to a title
instruction
0
77,500
91
232,090
Lilly to test baricitinib against COVID-19
output
1
77,500
91
232,091
Eli Lilly and Company and the US National Institute of Allergy and Infectious Diseases will study baricitinib, a Lilly rheumatoid arthritis drug, as a potential treatment for people with COVID-19 It’s thought that baricitinib’s anti-inflammatory effect could help reduce the cytokine storm that COVID-19 can trigger in p...
input
2
77,500
91
232,092
Please summerize the given abstract to a title
instruction
0
77,656
91
232,558
Alemtuzumab in Covid era
output
1
77,656
91
232,559
BACKGROUND: The SARS-CoV-2 pandemic impact on people with Multiple Sclerosis (pwMS) continues to worry. The disease modifying therapies in pwMS can add a more severe risk of infection when compared to the general population. Alemtuzumab is an anti-CD52 monoclonal antibody and it is one of the most immunosuppressive dru...
input
2
77,656
91
232,560
Please summerize the given abstract to a title
instruction
0
77,776
91
232,918
JAK/STAT Pathway Inhibition May Be a Promising Therapy for COVID-19-Related Hyperinflammation in Hematologic Patients
output
1
77,776
91
232,919
COVID-19 has rapidly become a major concern for the health systems worldwide. Its high contagiousness and associated mortality demand the discovery of helpful interventions with promising safety profile. Here, we report 3 severe COVID-19 cases, which achieved rapid and sustained improvement in outcome with the use of r...
input
2
77,776
91
232,920
Please summerize the given abstract to a title
instruction
0
77,787
91
232,951
Therapeutic safety and efficacy of triple-immunosuppressants versus dual-immunosuppressants in severe-to-critical COVID-19: a prospective cohort study in Bangladesh
output
1
77,787
91
232,952
BACKGROUND: Hyperinflammation-induced respiratory failure is a leading cause of mortality in COVID-19 infection. Immunosuppressants such as, Baricitinib and interleukin inhibitors are the drug-of-choice to suppress cytokine storm in COVID-19. Here, we compared the therapeutic safety and efficacy of triple-immunosuppres...
input
2
77,787
91
232,953
Please summerize the given abstract to a title
instruction
0
77,830
91
233,080
Ribavirin therapy for severe COVID-19: a retrospective cohort study
output
1
77,830
91
233,081
The aim of this study was to compare ribavirin therapy versus supportive therapy only for patients with severe coronavirus disease 2019 (COVID-19). A total of 115 patients with laboratory-confirmed COVID-19 were retrospectively analysed. All patients received supportive care as well as regular laboratory and clinical m...
input
2
77,830
91
233,082
Please summerize the given abstract to a title
instruction
0
77,844
91
233,122
High-Dose Intravenous Immunoglobulin in Severe Coronavirus Disease 2019: A Multicenter Retrospective Study in China
output
1
77,844
91
233,123
Background: The effective treatment of coronavirus disease 2019 (COVID-19) remains unclear. We reported successful use of high-dose intravenous immunoglobulin (IVIg) in cases of severe COVID-19, but evidence from larger case series is still lacking. Methods: A multi-center retrospective study was conducted to evaluate ...
input
2
77,844
91
233,124
Please summerize the given abstract to a title
instruction
0
77,890
91
233,260
Can pulse steroid therapy increase the risk of infection by COVID-19 in patients with multiple sclerosis?
output
1
77,890
91
233,261
BACKGROUND: Iran is one of the countries with a high prevalence of multiple sclerosis (MS) and COVID-19.MS patients receiving the immunomodulatory or immunosuppressive therapy have a higher risk of infection. Due to the significance of determining the risk factors for getting COVID-19 among MS patients, the present stu...
input
2
77,890
91
233,262
Please summerize the given abstract to a title
instruction
0
77,912
91
233,326
Anti-inflammatory effects of GLP-1 in patients with COVID-19
output
1
77,912
91
233,327
INTRODUCTION: Understanding the pathogenesis and risk factors to control the coronavirus disease 2019 (COVID-19) is necessary. Due to the importance of the inflammatory pathways in the pathogenesis of COVID-19 patients, evaluating the effects of anti-inflammatory medications is important. Glucagon-like peptide 1 recept...
input
2
77,912
91
233,328
Please summerize the given abstract to a title
instruction
0
77,922
91
233,356
A comparison of Remdesivir versus gold cluster in COVID-19 animal model: A better therapeutic outcome of gold cluster
output
1
77,922
91
233,357
While gold compound have been approved for Rheumatoid arthritis treatment as it well suppresses inflammatory cytokines of patients, no such treatment is currently available for COVID-19 treatment in vivo . We firstly disclose gold cluster yields better therapeutic outcome than Remdesivir in COVID-19 hamster treatments ...
input
2
77,922
91
233,358
Please summerize the given abstract to a title
instruction
0
77,961
91
233,473
Maoto, a traditional herbal medicine, for post-exposure prophylaxis for Japanese healthcare workers exposed to COVID-19: A single center study
output
1
77,961
91
233,474
Background Little research has been done on post-exposure prophylaxis (PEP) for COVID-19. This study was done to determine if maoto, a traditional herbal medicine commonly used for diseases with symptoms similar to those of COVID-19, can be repurposed for post-exposure prophylaxis to prevent the spread of nosocomial in...
input
2
77,961
91
233,475
Please summerize the given abstract to a title
instruction
0
77,992
91
233,566
Toxicity of psychotropic drugs in patients with COVID-19: A systematic review
output
1
77,992
91
233,567
OBJECTIVE: Due to the global spread of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), guidance for the use of psychotropic drugs in this context is necessary. We aimed to review clinical evidence regarding the potential toxicity of psychiatric medications in the context of SARS-CoV-2 infection. METHODS: ...
input
2
77,992
91
233,568
Please summerize the given abstract to a title
instruction
0
78,097
91
233,881
Glucocorticoids alone versus tocilizumab alone or glucocorticoids plus tocilizumab in patients with severe SARS-CoV-2 pneumonia and mild inflammation./ Glucocorticoides solos versus tocilizumab solo o glucocorticoides más tocilizumab en pacientes con neumonía grave por SARS-CoV-2 e inflamación moderada
output
1
78,097
91
233,882
AIM: To assess clinical outcomes according to the immunosuppressive treatment administered to patients with severe SARS-CoV-2 pneumonia and moderate inflammation. METHODS: A retrospective observational cohort study involving 142 patients with severe COVID-19 pneumonia and moderate inflammation divided into three treatm...
input
2
78,097
91
233,883
Please summerize the given abstract to a title
instruction
0
78,102
91
233,896
Safety and Effectiveness of High-Dose Vitamin C in Patients with COVID-19;A Randomized Controlled open-label Clinical Trial ‎
output
1
78,102
91
233,897
Background: To assess the effectiveness of vitamin C treatment against coronavirus disease 2019 (COVID-19) Methods: An open-label, randomized, and controlled trial was conducted on patients with severe COVID-19 infection. The case and control treatment groups each consisted of 30 patients. The control group received lo...
input
2
78,102
91
233,898
Please summerize the given abstract to a title
instruction
0
78,324
91
234,562
Impact of anti-cancer therapy on disease severity and mortality in cancer patients with COVID-19: a systematic review and meta-analysis
output
1
78,324
91
234,563
Background: Cancer patients are more vulnerable to Coronavirus disease-2019 (COVID-19) and have a higher risk of adverse outcomes than the general population. Therefore, it is necessary to evaluate whether anti-cancer therapies such as surgery, chemotherapy, immunotherapy, and targeted therapy will increase the severit...
input
2
78,324
91
234,564
Please summerize the given abstract to a title
instruction
0
78,450
91
234,940
[natural Therapeutic Factors in Medical Rehabilitation of Patients with Post-covid-19 at Outpatient Treatment Stage]
output
1
78,450
91
234,941
The purpose of the research is to study therapeutic efficiency of medical rehabilitation of patients with Post-COVID-19 syndrome at outpatient treatment stage including natural therapeutic factors and phyto products in rehabilitation programme. In Nalchik resort 64 patients suffering from corona virus disease COVID-19 ...
input
2
78,450
91
234,942
Please summerize the given abstract to a title
instruction
0
78,513
91
235,129
Systematic Review and Meta-Analysis of Tocilizumab Administration for the Treatment of Hospitalised Patients with COVID-19
output
1
78,513
91
235,130
Background: Tocilizumab, an IL-6 inhibitor, has been repurposed against the “cytokine storm” in the setting of COVID-19. In this systematic review and meta-analysis, we evaluated the efficacy of tocilizumab in the management of hospitalised COVID-19.Methods: We searched MEDLINE, CENTRAL and medRxiv for studies of tocil...
input
2
78,513
91
235,131
Please summerize the given abstract to a title
instruction
0
78,649
91
235,537
Evaluation of Ivermectin as a Potential Treatment for Mild to Moderate COVID-19: A Double-Blind Randomized Placebo Controlled Trial in Eastern India.
output
1
78,649
91
235,538
BACKGROUND There has been a growing interest in ivermectin ever since it was reported to have an in-vitro activity against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This trial was conducted to test the efficacy of ivermectin in mild and moderate coronavirus disease 19 (COVID-19). METHODS A double bl...
input
2
78,649
91
235,539
Please summerize the given abstract to a title
instruction
0
78,776
91
235,918
Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19
output
1
78,776
91
235,919
The repurposing of colchicine for the treatment of COVID-19 was suggested based in its immunomodulatory, anti-inflammatory, and anti-viral properties. We performed a single-center propensity score matched cohort study, including all consecutive COVID-19 patients admitted to a community hospital between 1 March 2020 and...
input
2
78,776
91
235,920
Please summerize the given abstract to a title
instruction
0
78,888
91
236,254
A PHARMACOLOGICAL FRAMEWORK FOR INTEGRATING TREATING THE HOST, REPURPOSING AND THE DAMAGE RESPONSE FRAMEWORK IN COVID‐19
output
1
78,888
91
236,255
With any new disease a framework for development of preventative or treatment therapeutics is key; the absence of such in COVID‐19 has enabled ineffective and potentially unsafe treatments to be taken up by Governments and clinicians desperate to have options for patients. As we still have few therapies and nil vaccine...
input
2
78,888
91
236,256
Please summerize the given abstract to a title
instruction
0
78,986
91
236,548
LB1. Remdesivir for the Treatment of High-Risk Non-Hospitalized Individuals With COVID-19: A Randomized, Double-Blind, Placebo-Controlled Trial
output
1
78,986
91
236,549
BACKGROUND: Remdesivir (RDV) is a potent nucleotide prodrug inhibitor of the SARS-CoV-2 RNA-dependent RNA polymerase that has demonstrated efficacy in the treatment of patients hospitalized with moderate to severe COVID-19. This Phase 3 (GS-US-540–9012) double-blind, placebo-controlled study compared the efficacy and s...
input
2
78,986
91
236,550
Please summerize the given abstract to a title
instruction
0
78,999
91
236,587
Safety of DW-MSC infusion in patients with low clinical risk COVID-19 infection: a randomized, double-blind, placebo-controlled trial
output
1
78,999
91
236,588
BACKGROUND: Due to their immunomodulatory properties, mesenchymal stem cells (MSCs) have been proposed to have therapeutic potential to improve clinical outcomes in COVID-19. However, the safety and efficacy profile of MSC infusion therapy in patients with non-severe COVID-19 infection has not been completely establish...
input
2
78,999
91
236,589
Please summerize the given abstract to a title
instruction
0
79,065
91
236,785
Convalescent plasma in the management of moderate covid-19 in adults in India: open label phase II multicentre randomised controlled trial (PLACID Trial)
output
1
79,065
91
236,786
OBJECTIVE: To investigate the effectiveness of using convalescent plasma to treat moderate coronavirus disease 2019 (covid-19) in adults in India. DESIGN: Open label, parallel arm, phase II, multicentre, randomised controlled trial. SETTING: 39 public and private hospitals across India. PARTICIPANTS: 464 adults (≥18 ye...
input
2
79,065
91
236,787
Please summerize the given abstract to a title
instruction
0
79,308
91
237,514
Aerosolized nanoliposomal carrier of remdesivir: an effective alternative for COVID-19 treatment in vitro
output
1
79,308
91
237,515
Aim: To formulate an aerosolized nanoliposomal carrier for remdesivir (AL-Rem) against coronavirus disease 2019. Methods: AL-Rem was prepared using modified hydration technique. Cytotoxicity in lung adenocarcinoma cells, stability and aerodynamic characteristics of developed liposomes were evaluated. Results: AL-Rem sh...
input
2
79,308
91
237,516
Please summerize the given abstract to a title
instruction
0
79,316
91
237,538
Antipsychotic-Induced Immune Dysfunction: A Consideration for COVID-19 Risk
output
1
79,316
91
237,539
Patients with severe mental illness are more susceptible to infections for a variety of reasons, some associated with the underlying disease and some due to environmental factors including housing insecurity, smoking, poor access to healthcare, and medications used to treat these disorders. This increased susceptibilit...
input
2
79,316
91
237,540
Please summerize the given abstract to a title
instruction
0
79,555
91
238,255
Rapid review of suspected adverse drug events due to remdesivir in the WHO database; findings and implications
output
1
79,555
91
238,256
Objectives: Remdesivir has shown promise in the management of patients with COVID-19 although recent studies have shown concerns with its effectiveness in practice. Despite this there is a need to document potential adverse drug events (ADEs) to guide future decisions as limited ADE data available before the COVID-19 p...
input
2
79,555
91
238,257
Please summerize the given abstract to a title
instruction
0
79,569
91
238,297
Efficacy of Brazilian Green Propolis (EPP-AF®) as an adjunct treatment for hospitalized COVID-19 patients: a randomized, controlled clinical trial
output
1
79,569
91
238,298
BACKGROUND: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) promotes challenging immune and inflammatory phenomena. Though various therapeutic possibilities have been tested against coronavirus disease 2019 (COVID-19), the most adequate treatment has not yet been established. Propolis is a natural product ...
input
2
79,569
91
238,299
Please summerize the given abstract to a title
instruction
0
79,576
91
238,318
Hospital admissions in inflammatory rheumatic diseases during the COVID-19 pandemic: incidence and role of disease modifying agents
output
1
79,576
91
238,319
Background: In this pandemia, it is essential for rheumatologist and patients to know the relationship between COVID-19 and inflammatory rheumatic diseases (IRD). We want to assess the role of targeted synthetic or biologic disease modifying antirheumatic drugs (ts/bDMARDs) and other variables in the development of mod...
input
2
79,576
91
238,320
Please summerize the given abstract to a title
instruction
0
79,677
91
238,621
Association Between Treatments and Short-Term Biochemical Improvements and Clinical Outcomes in Post-Severe Acute Respiratory Syndrome Coronavirus-2 Inflammatory Syndrome
output
1
79,677
91
238,622
OBJECTIVES: To 1) analyze the short-term biochemical improvements and clinical outcomes following treatment of children with post-severe acute respiratory syndrome coronavirus-2 inflammatory syndrome (multisystem inflammatory syndrome in children/pediatric inflammatory multisystem syndrome temporally associated with se...
input
2
79,677
91
238,623
Please summerize the given abstract to a title
instruction
0
79,730
91
238,780
The potential health and economic impact of dexamethasone treatment for patients with COVID-19
output
1
79,730
91
238,781
Dexamethasone has been shown to reduce mortality in hospitalised COVID-19 patients needing oxygen and ventilation by 18% and 36%, respectively. Here, we estimate the potential number of lives saved and life years gained if this treatment would be rolled out in the UK and globally, as well as its cost-effectiveness of i...
input
2
79,730
91
238,782
Please summerize the given abstract to a title
instruction
0
79,758
91
238,864
Antibiotic Prescribing Patterns at COVID-19 Dedicated Wards in Bangladesh: Findings from a Single Center Study
output
1
79,758
91
238,865
Background: As evidence is mounting regarding irrational and often unnecessary use of antibiotics during the COVID-19 pandemic a cross-sectional Point Prevalence Survey (PPS) (in accordance with WHO guideline) was conducted across COVID-19 dedicated wards in Dhaka Medical College and Hospital (DMCH). Methodology: Antib...
input
2
79,758
91
238,866
Please summerize the given abstract to a title
instruction
0
79,760
91
238,870
End of preview. Expand in Data Studio

Dataset Card for "med_alpaca_standardized_cluster_91_std"

More Information needed

Downloads last month
2